Reset

Advanced Filters
Saturday


Objectives:
  • Review the effects of the COVID-19 pandemic on cancer care.
  • Describe the difficulties cancer centers have faced with patient access during the pandemic, and the strategies implemented to ensure that high-risk patients continue to be treated.
  • Discuss the importance of considering alternate sites of care in the current healthcare market.
  • Describe the benefits and challenges associated with the use of telemedicine for treating patients with cancer, as well as recommendations for post-pandemic utility of telemedicine in the oncology setting.
03:30pm - 05:00pm EDT - March 20, 2021

Saturday
03:30pm - 04:15pm EDT - March 20, 2021
Track: Clinical Updates in Oncology


Objectives:
  • Review the recommended actionable oncogenic biomarkers for eligible patients with metastatic non-small cell lung cancer (NSCLC).
  • Identify the recommended immune biomarkers for eligible patients with metastatic NSCLC.
  • Describe the need for biomarker testing for eligible patients with metastatic NSCLC.
Saturday
03:30pm - 04:15pm EDT - March 20, 2021
Track: Clinical Updates in Oncology


Objectives:
  • List the patient and case-specific factors that should inform first-line treatment of melanoma brain metastases.
  • Identify multidisciplinary team members needed and patient/case characteristics that should inform treatment selection in patients with melanoma brain metastases.
  • Describe approaches for managing symptoms and quality of life issues for patients with melanoma brain metastases.
Saturday


Objectives:
  • Describe the current role of primary care physicians (PCPs) in cancer care.
  • Explain the importance of having PCPs as part of the oncology care team.
  • Identify ways to increase PCP involvement in cancer care.
Saturday
04:15pm - 05:00pm EDT - March 20, 2021
Track: Clinical Updates in Oncology


Objectives:
  • Review the specific appropriate targeted therapy for patients with metastatic non-small cell lung cancer (NSCLC) who have certain actionable oncogenic biomarkers.
  • Describe the appropriate immunotherapy regimens for patients with metastatic NSCLC who are not eligible for targeted therapies.
  • Select the optimal treatment for their patients with metastatic NSCLC.
Saturday
04:15pm - 05:00pm EDT - March 20, 2021
Track: Clinical Updates in Oncology


Objectives:
  • Describe clinical contexts in which molecular testing may be useful for management of cutaneous melanoma.
  • Explain the challenges to using and interpreting molecular testing for diagnostic or prognostic purposes.
  • Review molecular testing options for patients with stage III or stage IV disease, what material should be used for testing, and how results may inform treatment decisions.